尿素サイクル障害治療市場 - 世界の産業規模、シェア、動向、機会、予測、2017-2027酵素欠損タイプ別(カルバミルリン酸合成酵素(CPS1)、N-アセチルグルタミン酸合成酵素(NAGS)、オルニチントランスカルバミラーゼ(OTC欠損)、アルギニノコハク酸合成酵素(AS)、アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ)、アルギナーゼ(AG))、治療タイプ別(アミノ酸製剤、フェニル酪酸塩、安息香酸ナトリウム、その他)、投与経路別(経口/静脈)、流通チャネル別(病院薬局、小売薬局、オンライン薬局)、企業別、地域別Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027Segmented By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)), By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others), By Route of Administration (Oral v/s Intravenous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region 世界の尿素サイクル障害治療市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、尿素サイクル障害の有病率の増加、広範な研究開発が世界的な市場の成長を牽引しています。... もっと見る
サマリー世界の尿素サイクル障害治療市場は、予測期間2023-2027年に目覚ましい成長を遂げると予測されている。主な要因としては、尿素サイクル障害の有病率の増加、広範な研究開発が世界的な市場の成長を牽引しています。尿素サイクル障害(UCD)は、肝周囲細胞で尿素サイクルを構成する遺伝子異常のグループである。市場の成長を支えるその他の要因としては、政府による研究開発活動への投資の増加、主要企業によるイニシアチブの増加、大衆の意識の高まり、より良い医療サービスの存在、革新的な診断アプローチの増加などが挙げられる。人口における尿素サイクル障害の有病率の上昇 尿素サイクル障害の有病率の増加は、世界的な市場の成長を促進する可能性が高い。米国疾病予防管理センター(CDC)が発表した報告によると、尿素サイクル障害の予測発生率は出生8500人に1人である。多くの症例が未診断のままであり、障害を持つ新生児は完全な診断がつかないまま死亡するため、正確な数は不明である。乳幼児突然死症候群(SIDS)の症例の最大20%は、尿素サイクル障害のような先天性代謝異常の未診断に起因すると考えられており、尿素サイクル障害治療市場を刺激すると予想されている。 患者における取り組みと意識の高まり 過去数年にわたり、各国の政府や民間団体は、市場の成長を後押しするためにいくつかの措置を講じてきた。研究開発への多額の投資、認知度向上プログラムの増加、広範な研究活動や臨床試験、規制機関による承認の容易さといったイニシアチブの高まりが、市場を支える要因となっている。例えば、2017年にミード・ジョンソン・ニュートリション・カンパニー(MJN)はレキット・ベンキーザー・グループplc(RB)との合併を宣言した。RBの一部門となったミード・ジョンソンは、尿素サイクル障害の食事管理に使用されるEnfaとNutramigenをRBのコンシューマーヘルス・ポートフォリオに組み込み、世界的に認知されたブランドを獲得し、世界的な地位を強化した。同様に、2017年にHorizon Pharma plcは、尿素サイクル障害に苦しむ個人のためのイニシアチブであるUCD in Commonを立ち上げ、UCD患者、その家族、医療専門家に教育的、支援的、双方向的なリソースを提供している。 市場区分 世界の尿素サイクル障害治療市場は、酵素欠損タイプ、治療タイプ、投与経路、流通チャネル、企業ごとに区分される。酵素欠損タイプに基づくと、市場はカルバミルリン酸合成酵素(CPS1)、N-アセチルグルタミン酸合成酵素(NAGS)、オルニチントランスカルバミラーゼ(OTC欠損症)、アルギニノコハク酸合成酵素(AS)、アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ)、アルギナーゼ(AG)に分けられる。治療薬の種類により、市場はアミノ酸製剤、フェニル酪酸塩、安息香酸ナトリウム、その他に分けられる。投与経路に基づき、市場は経口投与と静脈内投与に分けられる。流通チャネルでは、病院薬局、小売薬局、オンライン薬局に分けられる。国別では、米国は尿素サイクル疾患の患者数が増加していることから、予測期間において有利な市場になると予想される。 市場プレイヤー Bausch Health Companies Inc.、Recordati Rare Diseases、Eurocept Pharmaceuticals Holding(Lucane Pharma SA)、Acer Therapeutics、Ultragenyx Pharmaceutical、Aeglea BioTherapeutics、Arcturus Therapeutics, Inc.、Orpharma Pty Ltd.、Selecta Biosciences, Inc.、Abbott Laboratories, Inc.などは、この市場で事業を展開している大手企業です。 報告書の範囲 本レポートでは、世界の尿素サイクル障害治療市場を、業界動向に加えて、以下のカテゴリーに分類しています: - 尿素サイクル障害治療市場:酵素欠損タイプ別 o カルバミルリン酸合成酵素(CPS1) o N-アセチルグルタミン酸合成酵素(NAGS) o オルニチントランスカルバミラーゼ(OTC欠損症) o アルギニノコハク酸合成酵素(AS) o アルギニノコハク酸リアーゼ(ALまたはASAリアーゼ) o アルギナーゼ(AG) - 尿素サイクル障害治療市場、治療タイプ別 o アミノ酸製剤 o フェニル酪酸塩 o 安息香酸ナトリウム o その他 - 尿素サイクル障害治療薬市場:投与経路別 o 経口剤 o 静注 - 尿素サイクル障害治療薬市場:流通経路別 o 病院薬局 o 小売薬局 o オンライン薬局 - 尿素サイクル障害治療市場:地域別 o 北米 米国 カナダ メキシコ o アジア太平洋 中国 インド 日本 オーストラリア 韓国 ヨーロッパ & CIS ドイツ フランス イギリス スペイン イタリア o 南米 ブラジル アルゼンチン コロンビア o 中東・アフリカ 南アフリカ サウジアラビア UAE 競争環境 企業プロフィール:尿素サイクル障害治療市場に参入している主要企業の詳細分析 利用可能なカスタマイズ: TechSci Research社は、与えられた市場データをもとに、企業固有のニーズに応じたカスタマイズを提供しています。本レポートでは以下のカスタマイズが可能です: 企業情報 - 追加市場プレイヤー(最大5社)の詳細分析とプロファイリング 目次1. Product Overview2. Research Methodology 3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market 4. Voice of Customer 5. Executive Summary 6. Global Urea Cycle Disorders Treatment Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)) 6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others) 6.2.3. By Route of Administration (Oral v/s Intravenous) 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 6.2.5. By Company (2021) 6.2.6. By Region 6.3. Market Map 7. North America Urea Cycle Disorders Treatment Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Enzyme Deficiency Type 7.2.2. By Treatment Type 7.2.3. By Route of Administration 7.2.4. By Distribution Channel 7.2.5. By Country 7.3. North America: Country Analysis 7.3.1. United States Urea Cycle Disorders Treatment Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Enzyme Deficiency Type 7.3.1.2.2. By Treatment Type 7.3.1.2.3. By Route of Administration 7.3.1.2.4. By Distribution Channel 7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Enzyme Deficiency Type 7.3.2.2.2. By Treatment Type 7.3.2.2.3. By Route of Administration 7.3.2.2.4. By Distribution Channel 7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Enzyme Deficiency Type 7.3.3.2.2. By Treatment Type 7.3.3.2.3. By Route of Administration 7.3.3.2.4. By Distribution Channel 8. Europe Urea Cycle Disorders Treatment Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Enzyme Deficiency Type 8.2.2. By Treatment Type 8.2.3. By Route of Administration 8.2.4. By Distribution Channel 8.2.5. By Country 8.3. Europe: Country Analysis 8.3.1. France Urea Cycle Disorders Treatment Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Enzyme Deficiency Type 8.3.1.2.2. By Treatment Type 8.3.1.2.3. By Route of Administration 8.3.1.2.4. By Distribution Channel 8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Enzyme Deficiency Type 8.3.2.2.2. By Treatment Type 8.3.2.2.3. By Route of Administration 8.3.2.2.4. By Distribution Channel 8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Enzyme Deficiency Type 8.3.3.2.2. By Treatment Type 8.3.3.2.3. By Route of Administration 8.3.3.2.4. By Distribution Channel 8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Enzyme Deficiency Type 8.3.4.2.2. By Treatment Type 8.3.4.2.3. By Route of Administration 8.3.4.2.4. By Distribution Channel 8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Enzyme Deficiency Type 8.3.5.2.2. By Treatment Type 8.3.5.2.3. By Route of Administration 8.3.5.2.4. By Distribution Channel 9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Enzyme Deficiency Type 9.2.2. By Treatment Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.2.5. By Country 9.3. Asia-Pacific: Country Analysis 9.3.1. China Urea Cycle Disorders Treatment Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Enzyme Deficiency Type 9.3.1.2.2. By Treatment Type 9.3.1.2.3. By Route of Administration 9.3.1.2.4. By Distribution Channel 9.3.2. India Urea Cycle Disorders Treatment Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Enzyme Deficiency Type 9.3.2.2.2. By Treatment Type 9.3.2.2.3. By Route of Administration 9.3.2.2.4. By Distribution Channel 9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Enzyme Deficiency Type 9.3.3.2.2. By Treatment Type 9.3.3.2.3. By Route of Administration 9.3.3.2.4. By Distribution Channel 9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook 9.3.4.1. Market Size & Forecast 9.3.4.1.1. By Value 9.3.4.2. Market Share & Forecast 9.3.4.2.1. By Enzyme Deficiency Type 9.3.4.2.2. By Treatment Type 9.3.4.2.3. By Route of Administration 9.3.4.2.4. By Distribution Channel 9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook 9.3.5.1. Market Size & Forecast 9.3.5.1.1. By Value 9.3.5.2. Market Share & Forecast 9.3.5.2.1. By Enzyme Deficiency Type 9.3.5.2.2. By Treatment Type 9.3.5.2.3. By Route of Administration 9.3.5.2.4. By Distribution Channel 10. South America Urea Cycle Disorders Treatment Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Enzyme Deficiency Type 10.2.2. By Treatment Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.2.5. By Country 10.3. South America: Country Analysis 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Enzyme Deficiency Type 10.3.1.2.2. By Treatment Type 10.3.1.2.3. By Route of Administration 10.3.1.2.4. By Distribution Channel 10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Enzyme Deficiency Type 10.3.2.2.2. By Treatment Type 10.3.2.2.3. By Route of Administration 10.3.2.2.4. By Distribution Channel 10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Enzyme Deficiency Type 10.3.3.2.2. By Treatment Type 10.3.3.2.3. By Route of Administration 10.3.3.2.4. By Distribution Channel 11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Enzyme Deficiency Type 11.2.2. By Treatment Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.2.5. By Country 11.3. MEA: Country Analysis 11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Enzyme Deficiency Type 11.3.1.2.2. By Treatment Type 11.3.1.2.3. By Route of Administration 11.3.1.2.4. By Distribution Channel 11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Enzyme Deficiency Type 11.3.2.2.2. By Treatment Type 11.3.2.2.3. By Route of Administration 11.3.2.2.4. By Distribution Channel 11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Enzyme Deficiency Type 11.3.3.2.2. By Treatment Type 11.3.3.2.3. By Route of Administration 11.3.3.2.4. By Distribution Channel 12. Market Dynamics 12.1. Drivers 12.2. Challenges 13. Market Trends & Developments 14. Competitive Landscape 14.1. Bausch Health Companies Inc. 14.2. Recordati Rare Diseases 14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA) 14.4. Acer Therapeutics 14.5. Ultragenyx Pharmaceutical 14.6. Aeglea BioTherapeutics 14.7. Arcturus Therapeutics, Inc. 14.8. Orpharma Pty Ltd. 14.9. Selecta Biosciences, Inc 14.10. Abbott Laboratories, Inc. 15. Strategic Recommendations
SummaryThe global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches. Table of Contents1. Product Overview2. Research Methodology 3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market 4. Voice of Customer 5. Executive Summary 6. Global Urea Cycle Disorders Treatment Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)) 6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others) 6.2.3. By Route of Administration (Oral v/s Intravenous) 6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) 6.2.5. By Company (2021) 6.2.6. By Region 6.3. Market Map 7. North America Urea Cycle Disorders Treatment Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Enzyme Deficiency Type 7.2.2. By Treatment Type 7.2.3. By Route of Administration 7.2.4. By Distribution Channel 7.2.5. By Country 7.3. North America: Country Analysis 7.3.1. United States Urea Cycle Disorders Treatment Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Enzyme Deficiency Type 7.3.1.2.2. By Treatment Type 7.3.1.2.3. By Route of Administration 7.3.1.2.4. By Distribution Channel 7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Enzyme Deficiency Type 7.3.2.2.2. By Treatment Type 7.3.2.2.3. By Route of Administration 7.3.2.2.4. By Distribution Channel 7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Enzyme Deficiency Type 7.3.3.2.2. By Treatment Type 7.3.3.2.3. By Route of Administration 7.3.3.2.4. By Distribution Channel 8. Europe Urea Cycle Disorders Treatment Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Enzyme Deficiency Type 8.2.2. By Treatment Type 8.2.3. By Route of Administration 8.2.4. By Distribution Channel 8.2.5. By Country 8.3. Europe: Country Analysis 8.3.1. France Urea Cycle Disorders Treatment Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Enzyme Deficiency Type 8.3.1.2.2. By Treatment Type 8.3.1.2.3. By Route of Administration 8.3.1.2.4. By Distribution Channel 8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Enzyme Deficiency Type 8.3.2.2.2. By Treatment Type 8.3.2.2.3. By Route of Administration 8.3.2.2.4. By Distribution Channel 8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Enzyme Deficiency Type 8.3.3.2.2. By Treatment Type 8.3.3.2.3. By Route of Administration 8.3.3.2.4. By Distribution Channel 8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Enzyme Deficiency Type 8.3.4.2.2. By Treatment Type 8.3.4.2.3. By Route of Administration 8.3.4.2.4. By Distribution Channel 8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Enzyme Deficiency Type 8.3.5.2.2. By Treatment Type 8.3.5.2.3. By Route of Administration 8.3.5.2.4. By Distribution Channel 9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Enzyme Deficiency Type 9.2.2. By Treatment Type 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.2.5. By Country 9.3. Asia-Pacific: Country Analysis 9.3.1. China Urea Cycle Disorders Treatment Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Enzyme Deficiency Type 9.3.1.2.2. By Treatment Type 9.3.1.2.3. By Route of Administration 9.3.1.2.4. By Distribution Channel 9.3.2. India Urea Cycle Disorders Treatment Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Enzyme Deficiency Type 9.3.2.2.2. By Treatment Type 9.3.2.2.3. By Route of Administration 9.3.2.2.4. By Distribution Channel 9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Enzyme Deficiency Type 9.3.3.2.2. By Treatment Type 9.3.3.2.3. By Route of Administration 9.3.3.2.4. By Distribution Channel 9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook 9.3.4.1. Market Size & Forecast 9.3.4.1.1. By Value 9.3.4.2. Market Share & Forecast 9.3.4.2.1. By Enzyme Deficiency Type 9.3.4.2.2. By Treatment Type 9.3.4.2.3. By Route of Administration 9.3.4.2.4. By Distribution Channel 9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook 9.3.5.1. Market Size & Forecast 9.3.5.1.1. By Value 9.3.5.2. Market Share & Forecast 9.3.5.2.1. By Enzyme Deficiency Type 9.3.5.2.2. By Treatment Type 9.3.5.2.3. By Route of Administration 9.3.5.2.4. By Distribution Channel 10. South America Urea Cycle Disorders Treatment Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Enzyme Deficiency Type 10.2.2. By Treatment Type 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.2.5. By Country 10.3. South America: Country Analysis 10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Enzyme Deficiency Type 10.3.1.2.2. By Treatment Type 10.3.1.2.3. By Route of Administration 10.3.1.2.4. By Distribution Channel 10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Enzyme Deficiency Type 10.3.2.2.2. By Treatment Type 10.3.2.2.3. By Route of Administration 10.3.2.2.4. By Distribution Channel 10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Enzyme Deficiency Type 10.3.3.2.2. By Treatment Type 10.3.3.2.3. By Route of Administration 10.3.3.2.4. By Distribution Channel 11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook 11.1. Market Size & Forecast 11.1.1. By Value 11.2. Market Share & Forecast 11.2.1. By Enzyme Deficiency Type 11.2.2. By Treatment Type 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.2.5. By Country 11.3. MEA: Country Analysis 11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook 11.3.1.1. Market Size & Forecast 11.3.1.1.1. By Value 11.3.1.2. Market Share & Forecast 11.3.1.2.1. By Enzyme Deficiency Type 11.3.1.2.2. By Treatment Type 11.3.1.2.3. By Route of Administration 11.3.1.2.4. By Distribution Channel 11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook 11.3.2.1. Market Size & Forecast 11.3.2.1.1. By Value 11.3.2.2. Market Share & Forecast 11.3.2.2.1. By Enzyme Deficiency Type 11.3.2.2.2. By Treatment Type 11.3.2.2.3. By Route of Administration 11.3.2.2.4. By Distribution Channel 11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook 11.3.3.1. Market Size & Forecast 11.3.3.1.1. By Value 11.3.3.2. Market Share & Forecast 11.3.3.2.1. By Enzyme Deficiency Type 11.3.3.2.2. By Treatment Type 11.3.3.2.3. By Route of Administration 11.3.3.2.4. By Distribution Channel 12. Market Dynamics 12.1. Drivers 12.2. Challenges 13. Market Trends & Developments 14. Competitive Landscape 14.1. Bausch Health Companies Inc. 14.2. Recordati Rare Diseases 14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA) 14.4. Acer Therapeutics 14.5. Ultragenyx Pharmaceutical 14.6. Aeglea BioTherapeutics 14.7. Arcturus Therapeutics, Inc. 14.8. Orpharma Pty Ltd. 14.9. Selecta Biosciences, Inc 14.10. Abbott Laboratories, Inc. 15. Strategic Recommendations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社の世界/地域別市場調査分野での最新刊レポート
本レポートと同じKEY WORD(urea)の最新刊レポートよくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/18 10:27 154.74 円 162.88 円 199.42 円 |